We have located links that may give you full text access.
The Clinical Value of Hepcidin in Breast Cancer and Its Bone Metastasis.
Annals of Clinical and Laboratory Science 2017 March
PURPOSE: We explored the role of hepcidin in the progression of breast cancer.
METHODS: A retrospective analysis of 25 breast cancer patients with bone metastases, 30 breast cancer patients without bone metastases, and 30 patients with breast hyperplasia was conducted to compare the differences in Hb, hepcidin, BMP6, IL-6, and sTfR among the three groups and explore the correlation of Hepcidin with BMP6 IL-6, Hb and sTfR. In addition, ROC analysis was performed to evaluate the diagnostic value of hepcidin, BMP6 and IL-6 in breast cancer and its bone metastasis, while multivariate Logistic regression analysis was conducted to compare various indicators in breast cancer and its bone metastasis.
RESULTS: The incidence of anemia was significantly different among three groups; hepcidin, BMP6, IL-6, sTfR, and Hb were also significantly different. Hepcidin level has a significant correlation with IL-6 and Hb levels in breast cancer patients with bone metastasis. Hepcidin had a higher diagnostic value for both breast cancer and breast cancer with bone metastasis than both BMP6 and IL-6. Hepcidin was an independent risk factor for breast cancer and its bone metastasis.
CONCLUSION: Hepcidin can very well be utilized as a potential prognostic marker to follow patients with breast cancer metastatic to bone.
METHODS: A retrospective analysis of 25 breast cancer patients with bone metastases, 30 breast cancer patients without bone metastases, and 30 patients with breast hyperplasia was conducted to compare the differences in Hb, hepcidin, BMP6, IL-6, and sTfR among the three groups and explore the correlation of Hepcidin with BMP6 IL-6, Hb and sTfR. In addition, ROC analysis was performed to evaluate the diagnostic value of hepcidin, BMP6 and IL-6 in breast cancer and its bone metastasis, while multivariate Logistic regression analysis was conducted to compare various indicators in breast cancer and its bone metastasis.
RESULTS: The incidence of anemia was significantly different among three groups; hepcidin, BMP6, IL-6, sTfR, and Hb were also significantly different. Hepcidin level has a significant correlation with IL-6 and Hb levels in breast cancer patients with bone metastasis. Hepcidin had a higher diagnostic value for both breast cancer and breast cancer with bone metastasis than both BMP6 and IL-6. Hepcidin was an independent risk factor for breast cancer and its bone metastasis.
CONCLUSION: Hepcidin can very well be utilized as a potential prognostic marker to follow patients with breast cancer metastatic to bone.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app